Grant Henning

Today we’re proud to welcome Dr. H. Henry Lai as our new Rubin H. Flocks Chair and department executive officer. Dr. Lai is just the sixth chair in the 111-year history of @UIowa_urology. As we look ahead to a new era, we also want to express our gratitude for Dr. Karl J. Kreder and his many years of service and leadership.

💬 Viewpoint: Adopting advanced, video-based performance analytics from elite sport could enhance surgical training by measuring technical, tactical, physical, and cognitive skills. ja.ma/3JpKwVS

We're well-represented at #ECIW2025 this weekend, including Dr. Kathryn Marchetti and incoming @UIowa_urology chair @HenryLaiMD, who was part of a great panel discussion on developing grant ideas. @AmerUrological

Excited to share our second year Urologic Oncology fellow, Dan Roberson, MD, as the featured SUO fellow in the most recent issue of @UrolOncol to honor the amazing accomplishments of SUO fellows. Click the link below to get to know @dsroberson93 better!  bit.ly/4naYx8z

New in @JAMAOnc: Our study of >11,000 PLCO participants shows that ~25% of elevated PSA values fall below threshold within a year, but persistent elevations rarely do (<10%), and should proceed directly to further eval. @SigridCarlsson @MariaPereMD @UrologyMSK @VickersBiostats

How fast do #rcc tumor thrombi grow? 📈 In our cohort @MayoUrology (n=141), venous tumor thrombi expanded ~1 cm/month (wide range). Faster growth seen with higher Mayo level, sarcomatoid/rhabdoid features & metastasis. These data can guide pre-op imaging & surgical triage.

Junior vs senior residents use surgical video review differently to learn RARP. @uroHenning & @MayoUrology team used a surgical intelligence platform to analyze 480 learning points in RARP. Promising use of video review in training 💡 New in @JEndourology liebertpub.com/doi/10.1177/08…

If you build it, they will come (to improve surgical skills). Embracing tech (@mytheator) for surgical video review and innovative training approaches makes @MayoUrology the envy of residency and fellowship programs across the country. @JEndourology liebertpub.com/doi/10.1177/08…

🚨 New in European Urology: Consolidative surgery after #EnfortumabVedotin +/– ICI in advanced urothelial carcinoma: ✅ 82% downstaging ✅ 43% ypT0N0 ✅ 79% stopped systemic therapy ✅ 89% DFS in curative group 📄 buff.ly/RFs0J5N #BladderCancer #Immunotherapy #Urology

@VickersBiostats @Moh_AhmedMD “Relatively minor harms” is relative. Why expose a patient to any additional harm? Always a balance of risks/benefits. Oversimplified to argue case closed here and current selection criteria is the best we can ever do

@Moh_AhmedMD At MSKCC we use the rule "if you aren't high enough risk for PLND, you aren't high risk enough for RP". Given the very major harms of RP (urinary, erectile dysfunction) vs. relatively minor harms of ePLND, why is "patient selection" such an issue?

When an RCT and an observational study have virtually identical results, you can be a little more definitive: ePLND offers zero biochemical recurrence benefits but does reduce metastasis

Congrats on @MayoUrology published study led by Drs @VRodriguezBravo and @DomingoDomenech discover that nucleoplasm-residing nucleoporins drive #ProstateCancer progression & immune evasion by switching on oncogenic signaling from deep within the nucleus! vist.ly/3z88z

H. Henry Lai, MD, has been named chair of the Department of Urology. He currently serves as the director of urologic research in the Division of Urologic Surgery and the Urology Residency program director at WashU Medicine in St. Louis. Welcome, Dr. Lai! uihealthcare.pulse.ly/qu3ffasrfr

Out now in @JUrology: In renal tumors >3 cm, cryoablation had higher local failure vs PN, but no difference in MFS or CSS. Despite 3 cm cutoff, our findings support cryoablation as a reasonable option in non-surgical candidates. Read here➡️bit.ly/4kw2mUe @WashU_Uro

Micropapillary histology in #BladderCancer: a retrospective survival analysis. @AlkazemiMD @UrologyMSK & @h_alahmadie @MSKCancerCenter join @UroDocAsh @MDAndersonNews to discuss a study on micropapillary bladder cancer where findings show worse survival vs. conventional UC (37 vs. 84 mos), with stage at dx as the key predictor. The % of micropapillary components didn’t impact prognosis. 🎥 #WatchNow > bit.ly/4iiZoRX

Treatment intensification strategies for high-risk #ProstateCancer patients. Aaron Berger, MD @auspecialists joins Eric Kim, MD @unevadareno to discuss a shift away from surgery & adjuvant RT, favoring early salvage guided by Decipher®. His group uses Orgovyx for ADT—fast-acting, no flare, in-house access. #WatchNow > bit.ly/4k55rdl @Decipher_VCYT

Dr. Arnold D. Bullock received the 2024 Medical Staff Association Lifetime Achievement Award! Since 1993, he's made an indelible impact on our department and the St. Louis community. Read more about Dr. Bullock here: bit.ly/41dKarF #WashUMedicine #WashUSurgery #Urology

Commentary @EUplatinum led by @d_shapiro1 on how the observed adjuvant immunotherapy trial result discrepancies in #kidneycancer can be explained by simple trial design principles: sciencedirect.com/science/articl…

Automated identification of key steps in robotic-assisted radical prostatectomy using #ArtificialIntelligence. @abhinav__khanna @MayoClinic joins @RuchikaTalwarMD @VUMCurology to discuss his team's work on #AI and #ProstateCancer surgery > bit.ly/3WpDLqH

@theusinghal @MayoUrology @SUO_YUO @UMichUrology Complete package right here - surgeon, researcher, mentor. Going to miss the fellas @theusinghal @UroR_Pessoa @rezanab but definitely exciting times ahead!